Suppr超能文献

多中心研究治疗老花眼的药物治疗。

A multicentric study of pharmacological treatment for presbyopia.

机构信息

Centro de Investigación Avanzada para la Presbicia, Buenos Aires, Argentina.

Universidad de Buenos Aires, Facultad de Odontología, Cátedra de Farmacología, Buenos Aires, Argentina.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2441-2450. doi: 10.1007/s00417-021-05138-8. Epub 2021 Mar 11.

Abstract

PURPOSE

To evaluate the safety, efficacy, and patient satisfaction with a pharmacological treatment of presbyopia performed with the Benozzi's method.

METHODS

A non-randomized multicentric case-series retrospective study was developed. Were included patients from 5 centers of Argentina, from January 2010 to June 2019, aged at baseline between 40 and 60 years old, with binocular uncorrected distance visual acuity (UDVA) of 25/20 or better, and with uncorrected near visual acuity (UNVA) at least Jaeger (J) 2 or worse. The treatment was performed with a patented formulation (pilocarpine and diclofenac preservative-free eye drops). The main outcome was binocular UNVA and UDVA. Differences were evaluated by paired t-test. The presence of side effects and patient's satisfaction were also evaluated. Data was analyzed in separated groups according to their follow-up time, from 2 to 10 years.

RESULTS

A total of 148 patients were included. At baseline, the UNVA for the different groups were between J3 and J8 which was improved to J1 to J2. The mean baseline UDVA has been ranged between 0.02 and 0.04 logMAR. The mean baseline UDVA has been ranged between 0.02 to 0.04 logMAR, after treatment were between 0.01 to 0.03, without a statisticallysignificant improvement. Side effects were spontaneously resolved, and subjective evaluation shows that patients were satisfied.

CONCLUSIONS

This first multicentric shows that Benozzi's method for presbyopia treatment was safety and improves the UNVA without affecting the UDVA, maintaining their efficacy even after 10 years, in a population aged between 40 and 60 years old, from different ophthalmic centers in Argentina.

摘要

目的

评估 Benozzi 法治疗老视的安全性、疗效和患者满意度。

方法

开展了一项非随机、多中心、回顾性病例系列研究。纳入了 2010 年 1 月至 2019 年 6 月来自阿根廷 5 个中心的患者,年龄基线在 40 至 60 岁之间,双眼未矫正远视力(UDVA)为 25/20 或更好,未矫正近视力(UNVA)至少为 Jaeger(J)2 或更差。治疗采用专利配方(毛果芸香碱和不含防腐剂的双氯芬酸滴眼液)。主要结局是双眼 UNVA 和 UDVA。采用配对 t 检验评估差异。还评估了不良反应的发生和患者的满意度。根据随访时间(2 至 10 年)将数据分为不同组进行分析。

结果

共纳入 148 例患者。基线时,不同组的 UNVA 介于 J3 和 J8 之间,改善至 J1 至 J2。平均基线 UDVA 在 0.02 至 0.04 logMAR 之间。治疗后的平均基线 UDVA 在 0.02 至 0.04 logMAR 之间,治疗后为 0.01 至 0.03,无统计学显著改善。不良反应自行缓解,主观评估显示患者满意。

结论

这是第一项多中心研究表明,Benozzi 法治疗老视安全有效,可改善 UNVA,而不影响 UDVA,即使在 10 年后,在年龄在 40 至 60 岁之间的人群中,在来自阿根廷不同眼科中心的人群中仍能保持疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验